Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 13/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482369 | 1.00 | HSD17B13 (0.47) | HSD17B13LMNAPOLBNPBWR1P2RY14 | |
| SCHEMBL31501594 | 0.91 | HSD17B13 (0.46) | HSD17B13LMNAPOLBNPBWR1P2RY14 | |
| SCHEMBL25431548 | 0.89 | HSD17B13 (0.51) | HSD17B13NPBWR1P2RY14KDM4EALDH1A1 | |
| SCHEMBL25373979 | 0.80 | HSD17B13 (0.61) | HSD17B13 | |
| SCHEMBL25377690 | 0.79 | HSD17B13 (0.76) | HSD17B13 | |
| SCHEMBL30482346 | 0.79 | HSD17B13 (0.76) | HSD17B13 | |
| SCHEMBL25431886 | 0.78 | NPBWR1 (0.42) | HSD17B13NPBWR1KDM4EALDH1A1GAA | |
| SCHEMBL30482284 | 0.78 | NPBWR1 (0.42) | HSD17B13NPBWR1KDM4EALDH1A1GAA | |
| SCHEMBL26230068 | 0.78 | NPBWR1 (0.42) | HSD17B13NPBWR1KDM4EALDH1A1GAA | |
| SCHEMBL26230397 | 0.71 | HSD17B13 (0.45) | HSD17B13LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100993-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4469451-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | Inipharm, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146897-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100993-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | HSD17B13 3/4885LMNA 1642/4885POLB 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.